Drug intelligence / Profile preview

ibuprofen + magnesium oxide

Development stage
Unknown
Lead developer
SSP
Modality
Small Molecules
Administration
Oral
01

Overview

Ibuprofen + magnesium oxide is an over-the-counter (OTC) combination analgesic developed by SS Pharmaceutical (a Sanofi company) and marketed primarily under the EVE brand in Japan. The combination utilizes "Quick Action Technology," where ibuprofen serves as the active pharmaceutical ingredient providing analgesic, anti-inflammatory, and antipyretic effects through the inhibition of cyclooxygenase enzymes (COX-1 and COX-2). Magnesium oxide is included as a formulation aid to increase the pH of the gastric microenvironment, which accelerates the dissolution and subsequent absorption of the acidic ibuprofen molecule, leading to a faster onset of pain relief. Additionally, magnesium oxide provides a mild antacid effect that may help protect the gastric mucosa from NSAID-induced irritation. It is indicated for the relief of headaches, menstrual pain (dysmenorrhea), fever, and other common types of pain.

Brand names
EVE QuickEVE Quick DX
Other names
Ibuprofen/Magnesium Oxide
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)

Beyond the preview

Go deeper on ibuprofen + magnesium oxide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ibuprofen + magnesium oxide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call